TACTICAL THERAPEUTICS is a Biopharmaceutical Company developing the next wave of safer and cost effective small molecule therapeutics with near term commercialization for treatment of cancer and other diseases. At the core of the Company’s technology are patented products, with the lead candidate, an angiogenesis inhibitor, called 1,2,3-carboxyamido-triazole orotate (CTO) that has unique pharmacokinetic properties of faster delivery to target cancer cells as well as a high clearance rate and reduced toxicity when compared with CAI, a drug tested in clinical trials by the National Cancer Institute for 20 years and abandoned. Specifically, CTO has overcome most of the disadvantages of CAI. The Company will develop CTO under the Accelerated Drug Approval Track.
The IND for CTO was approved in January 2010 for Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients with Advanced or Metastatic Solid Tumors and Titrated in Combination
Therapy with Temodar® in Patients with Glioblastoma Multiforme.
The Clinical studies are currently conducted at Four Clinical Sites
in the US. www.clinicaltrials.gov
Mission
To provide therapies that are more effective, less toxic and more cost effective than current cancer therapeutics by:
Targeting specific molecular targets with small molecules and developing translational therapies.
Modify chemical structures to make deliverable, safe and non-toxic drugs that can be given orally
Pharmacokinetic modulation to improve bioavailability, efficacy and clearance of drugs
Developing affordable and cost effective drugs for cancer patients worldwide
